Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Caution is needed in interpreting HIV transmission chains by ultra-deep sequencing.

Todesco E, Wirden M, Calin R, Simon A, Sayon S, Barin F, Katlama C, Calvez V, Marcelin AG, Hué S.

AIDS. 2018 Dec 21. doi: 10.1097/QAD.0000000000002105. [Epub ahead of print]

PMID:
30585843
2.

Evolution of the Envelope Glycoprotein of HIV-1 Clade B towards Higher Infectious Properties over the Course of the Epidemic.

Bouvin-Pley M, Beretta M, Moreau A, Roch E, Essat A, Goujard C, Chaix ML, Moiré N, Martin L, Meyer L, Barin F, Braibant M.

J Virol. 2018 Dec 19. pii: JVI.01171-18. doi: 10.1128/JVI.01171-18. [Epub ahead of print]

PMID:
30567994
3.

Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.

Stefic K, Bouvin-Pley M, Essat A, Visdeloup C, Moreau A, Goujard C, Chaix ML, Braibant M, Meyer L, Barin F.

J Virol. 2019 Jan 4;93(2). pii: e01492-18. doi: 10.1128/JVI.01492-18. Print 2019 Jan 15.

PMID:
30404804
4.

Innovative Approach for Enhancing Testing of HIV, Hepatitis B, and Hepatitis C in the General Population: Protocol for an Acceptability and Feasibility Study (BaroTest 2016).

Lydié N, Saboni L, Gautier A, Brouard C, Chevaliez S, Barin F, Larsen C, Lot F, Rahib D.

JMIR Res Protoc. 2018 Oct 12;7(10):e180. doi: 10.2196/resprot.9797.

5.

Phenotypic properties of envelope glycoproteins of transmitted HIV-1 variants from patients belonging to transmission chains.

Beretta M, Moreau A, Bouvin-Pley M, Essat A, Goujard C, Chaix ML, Hue S, Meyer L, Barin F, Braibant M; ANRS 06 Primo Cohort.

AIDS. 2018 Sep 10;32(14):1917-1926. doi: 10.1097/QAD.0000000000001906.

PMID:
29927786
6.

Time location sampling in men who have sex with men in the HIV context: the importance of taking into account sampling weights and frequency of venue attendance.

Sommen C, Saboni L, Sauvage C, Alexandre A, Lot F, Barin F, Velter A.

Epidemiol Infect. 2018 May;146(7):913-919. doi: 10.1017/S0950268818000675. Epub 2018 Apr 2.

PMID:
29606158
7.

Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection.

Stefic K, Novelli S, Mahjoub N, Seng R, Molina JM, Cheneau C, Barin F, Chaix ML, Meyer L, Delaugerre C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) PRIMO Study Group .

J Infect Dis. 2018 May 5;217(11):1793-1797. doi: 10.1093/infdis/jiy120.

PMID:
29509924
8.

[Trispecific broadly neutralizing antibodies for HIV immunoprophylaxis and immunotherapy?]

Barin F, Stefic K.

Med Sci (Paris). 2018 Feb;34(2):109-111. doi: 10.1051/medsci/20183402002. Epub 2018 Feb 16. French. No abstract available.

PMID:
29451475
9.

What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM.

Bendenoun M, Samri A, Avettand-Fènoël V, Cardinaud S, Descours B, Carcelain G, Mazeron MC, Bergmann JF, Urrutia A, Moris A, Rouzioux C, Simon F, Andre P, Pocard M, Dray X, Mourez T, Vieillard V, Autran B, Barin F, Sellier P.

EBioMedicine. 2018 Jan;27:51-60. doi: 10.1016/j.ebiom.2017.12.003. Epub 2017 Dec 7.

10.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals.

Unal G, Alessandri-Gradt E, Leoz M, Pavie J, Lefèvre C, Panjo H, Charpentier C, Descamps D, Barin F, Simon F, Meyer L, Plantier JC; ORIVAO Study .

Clin Infect Dis. 2018 May 17;66(11):1785-1793. doi: 10.1093/cid/cix1087.

PMID:
29272369
11.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.

Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group .

Clin Infect Dis. 2018 May 2;66(10):1588-1594. doi: 10.1093/cid/cix1070.

PMID:
29244143
12.

Massive Iatrogenic Outbreak of Human Immunodeficiency Virus Type 1 in Rural Cambodia, 2014-2015.

Rouet F, Nouhin J, Zheng DP, Roche B, Black A, Prak S, Leoz M, Gaudy-Graffin C, Ferradini L, Mom C, Mam S, Gautier C, Lesage G, Ken S, Phon K, Kerleguer A, Yang C, Killam W, Fujita M, Mean C, Fontenille D, Barin F, Plantier JC, Bedford T, Ramos A, Saphonn V.

Clin Infect Dis. 2018 May 17;66(11):1733-1741. doi: 10.1093/cid/cix1071.

13.

HIV transmission and pre-exposure prophylaxis in a high risk MSM population: A simulation study of location-based selection of sexual partners.

Robineau O, Velter A, Barin F, Boelle PY.

PLoS One. 2017 Nov 30;12(11):e0189002. doi: 10.1371/journal.pone.0189002. eCollection 2017.

14.

Beneficial effects of resistance training on the protein profile of the calcaneal tendon during aging.

Barin FR, Durigan JLQ, Oliveira KS, Migliolo L, Almeida JA, Carvalho M, Petriz B, Selistre-de-Araujo HS, Fontes W, Franco OL, Marqueti RC.

Exp Gerontol. 2017 Dec 15;100:54-62. doi: 10.1016/j.exger.2017.10.019. Epub 2017 Oct 21.

PMID:
29066418
15.

Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties.

Stefic K, Chaillon A, Bouvin-Pley M, Moreau A, Braibant M, Bastides F, Gras G, Bernard L, Barin F.

PLoS One. 2017 Aug 25;12(8):e0181680. doi: 10.1371/journal.pone.0181680. eCollection 2017.

16.

Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.

Hongjaisee S, Braibant M, Barin F, Ngo-Giang-Huong N, Sirirungsi W, Samleerat T.

AIDS Res Hum Retroviruses. 2017 Sep;33(9):946-951. doi: 10.1089/AID.2017.0044. Epub 2017 Jun 12.

17.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2351-2354. doi: 10.1093/jac/dkx128.

PMID:
28472307
18.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.

Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1769-1773. doi: 10.1093/jac/dkx042.

PMID:
28333232
19.

Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies.

Chaillon A, Essat A, Frange P, Smith DM, Delaugerre C, Barin F, Ghosn J, Pialoux G, Robineau O, Rouzioux C, Goujard C, Meyer L, Chaix ML; on behalf the ANRS PRIMO Cohort Study.

Retrovirology. 2017 Feb 21;14(1):15. doi: 10.1186/s12977-017-0339-4.

20.

APOL1 variants may induce HIV-associated nephropathy during HIV primary infection.

De Laroche M, Desbuissons G, Rouvier P, Barin F, Deray G, Caumes E, Katlama C, Tubiana R, Isnard Bagnis C.

J Antimicrob Chemother. 2017 May 1;72(5):1539-1541. doi: 10.1093/jac/dkw563. No abstract available.

PMID:
28100445
21.

Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011-2013.

Brouard C, Pillonel J, Sogni P, Chollet A, Lazarus JV, Pascal X, Barin F, Jauffret-Roustide M; ANRS Coquelicot Survey Group.

Epidemiol Infect. 2017 Jan 19:1-11. doi: 10.1017/S0950268816003137. [Epub ahead of print]

PMID:
28100289
22.

Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression.

Brice J, Sylla M, Sayon S, Telly F, Bocar-Fofana D, Murphy R, Lambert-Niclot S, Todesco E, Grude M, Barin F, Diallo S, Pillay D, Derache A, Calvez V, Marcelin AG, Maiga AI.

J Antimicrob Chemother. 2017 Apr 1;72(4):1147-1151. doi: 10.1093/jac/dkw537.

23.

Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys.

Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, Chevaliez S, Pillonel J, Jauffret-Roustide M, LE Strat Y.

Epidemiol Infect. 2017 Apr;145(5):895-907. doi: 10.1017/S0950268816002934. Epub 2016 Dec 22.

PMID:
28004616
24.

Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.

Stefic K, Salmona M, Capitao M, Splittgerber M, Maakaroun-Vermesse Z, Néré ML, Bernard L, Chaix ML, Barin F, Delaugerre C.

J Antimicrob Chemother. 2017 Mar 1;72(3):850-854. doi: 10.1093/jac/dkw507.

PMID:
27999055
25.

HIV surveillance combining an assay for identification of very recent infection and phylogenetic analyses on dried spots.

Brand D, Capsec J, Chaillon A, Cazein F, Le Vu S, Moreau A, Pillonel J, Brunet S, Thierry D, Guillon-Grammatico L, Lot F, Barin F.

AIDS. 2017 Jan 28;31(3):407-416. doi: 10.1097/QAD.0000000000001325.

PMID:
27831948
26.

HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks.

Cazein F, Pillonel J, Barin F, Jauffret-Roustide M.

AIDS. 2016 Jul 17;30(11):1857-8. doi: 10.1097/QAD.0000000000001115. No abstract available.

PMID:
27351929
27.

Characterizing the multiplicity of HIV founder variants during sexual transmission among MSM.

Chaillon A, Gianella S, Little SJ, Caballero G, Barin F, Kosakovsky Pond S, Richman DD, Smith DM, Mehta SR.

Virus Evol. 2016 Jun 8;2(1):vew012. doi: 10.1093/ve/vew012. eCollection 2016 Jan.

28.

Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey.

Weill-Barillet L, Pillonel J, Semaille C, Léon L, Le Strat Y, Pascal X, Barin F, Jauffret-Roustide M.

Rev Epidemiol Sante Publique. 2016 Sep;64(4):301-12. doi: 10.1016/j.respe.2015.10.003. Epub 2016 Feb 19.

PMID:
26904917
29.

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.

Morgand M, Bouvin-Pley M, Plantier JC, Moreau A, Alessandri E, Simon F, Pace CS, Pancera M, Ho DD, Poignard P, Bjorkman PJ, Mouquet H, Nussenzweig MC, Kwong PD, Baty D, Chames P, Braibant M, Barin F.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):237-45. doi: 10.1097/QAI.0000000000000854.

30.

Response to Hønge et al.: Comment on Gautheret-Dejean et al.: Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections.

Gautheret-Dejean A, Bocobza J, Brunet S, Damond F, Plantier JC, Barin F.

J Med Virol. 2016 Mar;88(3):369-70. doi: 10.1002/jmv.24390. Epub 2015 Oct 5. No abstract available.

PMID:
26399874
31.

Combining the Estimated Date of HIV Infection with a Phylogenetic Cluster Study to Better Understand HIV Spread: Application in a Paris Neighbourhood.

Robineau O, Frange P, Barin F, Cazein F, Girard PM, Chaix ML, Kreplak G, Boelle PY, Morand-Joubert L.

PLoS One. 2015 Aug 12;10(8):e0135367. doi: 10.1371/journal.pone.0135367. eCollection 2015.

32.

Comment on: Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database.

Grammatico-Guillon L, Gras G, Hassen-Khodja C, Maakaroun Z, Bastides F, Barin F, Bernard L.

J Antimicrob Chemother. 2015 Nov;70(11):3172-3. doi: 10.1093/jac/dkv242. Epub 2015 Aug 7. No abstract available.

PMID:
26253090
33.

Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections.

Gautheret-Dejean A, Bocobza J, Brunet S, Damond F, Plantier JC, Barin F.

J Med Virol. 2015 Dec;87(12):2061-6. doi: 10.1002/jmv.24282. Epub 2015 Jun 16.

PMID:
26081750
34.

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.

Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3.

PMID:
25558077
35.

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

Soulie C, Descamps D, Grudé M, Schneider V, Trabaud MA, Morand-Joubert L, Delaugerre C, Montes B, Barin F, Ferre V, Raymond S, Jeulin H, Alloui C, Yerly S, Pallier C, Reigadas S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS Resistance AC11 Group.

J Antimicrob Chemother. 2015 Feb;70(2):566-72. doi: 10.1093/jac/dku419. Epub 2014 Oct 25.

PMID:
25344810
36.

Characteristics of patients recently infected with HIV-1 non-B subtypes in France: a nested study within the mandatory notification system for new HIV diagnoses.

Brand D, Moreau A, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, Le Vu S, Plantier JC, Semaille C, Barin F.

J Clin Microbiol. 2014 Nov;52(11):4010-6. doi: 10.1128/JCM.01141-14. Epub 2014 Sep 17.

37.

Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.

Bouvin-Pley M, Morgand M, Meyer L, Goujard C, Moreau A, Mouquet H, Nussenzweig M, Pace C, Ho D, Bjorkman PJ, Baty D, Chames P, Pancera M, Kwong PD, Poignard P, Barin F, Braibant M.

J Virol. 2014 Dec;88(23):13910-7. doi: 10.1128/JVI.02083-14. Epub 2014 Sep 17.

38.

Estimating the timing of mother-to-child transmission of the human immunodeficiency virus type 1 using a viral molecular evolution model.

Chaillon A, Samleerat T, Zoveda F, Ballesteros S, Moreau A, Ngo-Giang-Huong N, Jourdain G, Gianella S, Lallemant M, Depaulis F, Barin F.

PLoS One. 2014 Apr 9;9(4):e90421. doi: 10.1371/journal.pone.0090421. eCollection 2014.

39.
40.

HIV-DNA in the genital tract of women on long-term effective therapy is associated to residual viremia and previous AIDS-defining illnesses.

Prazuck T, Chaillon A, Avettand-Fènoël V, Caplan AL, Sayang C, Guigon A, Niang M, Barin F, Rouzioux C, Hocqueloux L.

PLoS One. 2013 Aug 21;8(8):e69686. doi: 10.1371/journal.pone.0069686. eCollection 2013.

41.

Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.

Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, Braibant M.

PLoS Pathog. 2013;9(7):e1003477. doi: 10.1371/journal.ppat.1003477. Epub 2013 Jul 4.

42.

High viral loads among HIV-positive MSM attending gay venues: implications for HIV transmission.

Semaille C, Barin F, Bouyssou A, Peytavin G, Guinard J, Le Vu S, Pillonel J, Spire B, Velter A.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):e122-4. doi: 10.1097/QAI.0b013e31829002ae. No abstract available.

PMID:
23760098
43.

Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.

Braibant M, Gong EY, Plantier JC, Moreau T, Alessandri E, Simon F, Barin F.

AIDS. 2013 May 15;27(8):1239-44. doi: 10.1097/QAD.0b013e32835ecb42.

PMID:
23343910
44.

Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120.

Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F, Baty D, Martin L, Benichou S, Chames P.

J Virol. 2013 Jan;87(2):1137-49. doi: 10.1128/JVI.00461-12. Epub 2012 Nov 14.

45.

HIV prevalence and sexual risk behaviors associated with awareness of HIV status among men who have sex with men in Paris, France.

Velter A, Barin F, Bouyssou A, Guinard J, Léon L, Le Vu S, Pillonel J, Spire B, Semaille C.

AIDS Behav. 2013 May;17(4):1266-78. doi: 10.1007/s10461-012-0303-1.

PMID:
22968398
46.

Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.

Chaillon A, Braibant M, Hué S, Bencharif S, Enard D, Moreau A, Samri A, Agut H, Barin F.

PLoS One. 2012;7(8):e44163. doi: 10.1371/journal.pone.0044163. Epub 2012 Aug 30.

47.

HIV-1 CRF01_AE coreceptor usage prediction using kernel methods based logistic model trees.

Shoombuatong W, Hongjaisee S, Barin F, Chaijaruwanich J, Samleerat T.

Comput Biol Med. 2012 Sep;42(9):885-9. doi: 10.1016/j.compbiomed.2012.06.011. Epub 2012 Jul 21.

PMID:
22824642
48.

The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Chaillon A, Wack T, Braibant M, Mandelbrot L, Blanche S, Warszawski J, Barin F.

J Virol. 2012 Oct;86(19):10540-6. doi: 10.1128/JVI.00518-12. Epub 2012 Jul 18.

49.

Prevalence and characteristics of individuals with undiagnosed HIV infection in France: evidence from a survey on hepatitis B and C seroprevalence.

Cazein F, Barin F, Le Strat Y, Pillonel J, Le Vu S, Lot F, Thierry D, Meffre C, Semaille C.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):e114-7. doi: 10.1097/QAI.0b013e318256b3fd. No abstract available.

PMID:
22772350
50.

Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France.

Le Vu S, Velter A, Meyer L, Peytavin G, Guinard J, Pillonel J, Barin F, Semaille C.

PLoS One. 2012;7(6):e39872. doi: 10.1371/journal.pone.0039872. Epub 2012 Jun 29.

Supplemental Content

Support Center